文献速递甲状腺与颈部外科

T2N0M0期经典型甲状腺乳头状癌:男性及55岁以上患者全甲状腺切除联合放疗可改善总生存

Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer.
PubMed 文献 · Surgery · 2021-10-16

基于美国国家癌症数据库(2004-2016)cT2N0M0经典型甲状腺乳头状癌患者,比较腺叶切除与全甲状腺切除(±放疗)对总生存的影响。多因素分析显示18-55岁患者腺叶切除与全甲状腺切除生存相当;倾向性评分匹配后,男性和>55岁患者全甲状腺切除联合放疗较腺叶切除或单纯全甲状腺切除有总生存优势。

要点

  • cT2N0M0经典型乳头状癌,>55岁患者全甲状腺切除联合放疗较腺叶切除改善10年总生存。
  • 男性患者(18-90+岁合并)全甲状腺切除联合放疗较腺叶切除或单纯全甲状腺切除有生存优势。
  • 18-55岁患者腺叶切除与全甲状腺切除(±放疗)总生存无差异。

核心结论

  • 对于cT2N0M0经典型甲状腺乳头状癌,全甲状腺切除联合放疗可改善>55岁患者(男女合并队列)和男性患者(18-90+岁合并)的10年总生存。
  • 18-45岁和46-55岁患者(男女合并队列)腺叶切除与全甲状腺切除(±放疗)总生存相当。

研究设计与样本

  • 回顾性队列研究,纳入美国国家癌症数据库(2004-2016)cT2N0M0经典型甲状腺乳头状癌患者。
  • 采用多因素Cox回归比较腺叶切除与全甲状腺切除(±放疗)的总生存,并按年龄分层(18-45、46-55、>55岁)。
  • 另行1:1倾向性评分匹配,以Kaplan-Meier曲线估计10年总生存,log-rank检验按年龄和性别分层。

主要发现

  • 多因素分析中,18-45岁和46-55岁患者(男女合并队列)腺叶切除与全甲状腺切除(±放疗)总生存相当。
  • 倾向性评分匹配后,男性(18-90+岁合并)全甲状腺切除联合放疗较腺叶切除和单纯全甲状腺切除均有总生存优势。
  • 倾向性评分匹配后,>55岁患者(男女合并队列)全甲状腺切除联合放疗较腺叶切除有总生存优势。
  • 倾向性评分匹配后,女性(18-90+岁合并)及18-45岁、46-55岁患者(男女合并队列)接受腺叶切除、全甲状腺切除或全甲状腺切除联合放疗的总生存无差异。

临床怎么用

  • 对cT2N0M0经典型甲状腺乳头状癌的男性患者,可考虑全甲状腺切除联合放疗以改善总生存。
  • 对>55岁的cT2N0M0经典型甲状腺乳头状癌患者,可考虑全甲状腺切除联合放疗而非腺叶切除。
  • 对18-55岁患者,腺叶切除与全甲状腺切除(±放疗)总生存相当,决策时应结合其他因素个体化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We examine whether surgery extent and radiation administration affect overall survival for cT2N0M0 classic papillary thyroid cancer according to age and sex. METHODS: Patients with cT2N0M0 classic papillary thyroid cancer tumors in the National Cancer Data Base (2004-2016) were selected. Multivariable Cox regression analysis compared patients (combined male + female cohorts) having lobectomy to those having total thyroidectomy with or without radiation (primarily radioactive iodine) for ages: 18 to 45, 46 to 55, and >55 years. In addition, 1:1 propensity score matching and Kaplan-Meier curves with 10-year overall survival estimates, and log-rank test were stratified by age and sex. RESULTS: Lobectomy had equivalent overall survival to total thyroidectomy without and with radiation for patients (combined male + female cohorts) aged 18 to 45 and 46 to 55 years on multivariable analysis. On propensity score matching there was overall survival advantage for total thyroidectomy with radiation over both lobectomy and total thyroidectomy for men (ages 18-90+ combined) and overall survival advantage in patients (combined male + female cohort) aged >55 years having total thyroidectomy with radiation versus lobectomy. On propensity score matching there were no overall survival differences in women (ages 18-90+ combined) or patients (combined male + female cohort) aged 18 to 45 and 46 to 55 years having either lobectomy, total thyroidectomy, or total thyroidectomy with radiation. CONCLUSION: For cT2N0M0 classic papillary thyroid cancer, total thyroidectomy with radiation improves 10-year overall survival for patients (combined male + female cohort) aged >55 years and men (ages 18-90+ combined).

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. MacKinney EC, Kuchta KM, Winchester DJ, et al. Overall survival is improved with total thyroidectomy and radiation for male patients and patients older than 55 with T2N0M0 Stage 1 classic papillary thyroid cancer. Surgery. 2021. PMID: 34666913. doi:10.1016/j.surg.2021.08.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。